

2020 SUBJECT INDEX

1 year of age	248	Dysmenorrhea	7*suppl
11 β -hydroxylase deficiency	288	Education	95
46,XX disorder of sex development.....	109, 206	eHealth.....	225
46,XX ovotesticular disorder of sex development.....	308	Endometriosis	7*suppl
AAP	125	Epimutation	1
Abetalipoproteinemia	223	Euthyroid sick syndrome.....	143, 223
Abnormal external genitalia	113	Family planning.....	28*suppl
Abnormal uterine bleeding.....	1 *suppl	Final height	295
<i>Accelerator hypothesis</i>	281	Functional	18*suppl
Adherence	225	Genotype.....	1
Adiponectin	180	<i>GLI2</i> mutations	319
Adolescence	17	Glycemic control	233
Adolescent... 1*suppl, 18*suppl, 28*suppl, 41*suppl, 46*suppl, 50*suppl, 233		GnRH	37
Adrenal hypoplasia	206	GnRH analogue	37
Adrenal insufficiency	241	Gonadotropin releasing hormone agonist	37
Adult height	71	Graves' disease.....	197
Alkaline phosphatase	104	Growth	225
Androgen-insensitivity syndrome	50*suppl	Growth chart	125
Anti-Müllerian hormone	79	Growth disorders	130
Application	125	Growth hormone	225
Aromatase deficiency	109	Growth hormone deficiency	319
Autoimmune thyroiditis	303	Growth hormone treatment.....	295
Bisphenol A	86	Growth velocity	71
Body fat percentage.....	168	Guideline	125
Body mass index	281	Heavy menstrual bleeding.....	1*suppl
Calculator	125	Hormone replacement therapy.....	46*suppl
Carney complex	117	Human growth hormone treatment.....	71
Central hypothyroidism	218, 223	Hydroxymethylfurfural	79
Central precocious puberty	37	Hypertension.....	29, 125
Central puberty precocious.....	117	Hypogonadism	46*suppl
Childhood.....	17, 241	Hypophosphatasia.....	104
Children	29, 86, 180, 281, 329	Hypophosphatemic rickets	151
Children and adolescents	45	Hypopituitarism	261
Coagulopathy	1 *suppl	Hypoprolactinemia	218
Combined pituitary hormone deficiency	212, 261	Hypothalamic amenorrhea.....	18*suppl
Congenital adrenal hyperplasia.....	288	IGF-I	130
Congenital hypothyroidism.....	275, 303	IGFBP-3	130
Contraception.....	28*suppl	<i>IGSF1</i>	218
Contraceptive services.....	28*suppl	Imprinting disorders	1
Counselling.....	28*suppl	Incidence	288
<i>CYP19A1</i> gene	109	Incidence rate	175
Cyprus.....	175	Increased intestinal permeability.....	303
D-lactate.....	160	Insulin	189
Deficiency	248	Insulin resistance.....	180
Developmental disabilities.....	41*suppl	Internipple distance	269
Diabetes mellitus.....	189, 315	Internipple index	269
Diabetic ketoacidosis	160, 189	Intramuscular ACTH	241
Diagnosis	18*suppl	Iodine	329
Double diabetes	55	Iodine deficiency	256
		Irisin.....	168

2020 SUBJECT INDEX

Ischemia-modified albumin	45	<i>PHEX</i>	151
Isolated growth hormone deficiency	295	Pituitary stalk interruption syndrome	71, 212
Knowledge levels	95	Pituitary transcription factors	261
Large cell calcifying Sertoli cell tumor	117	Polydactyly	319
Leuprolide	37	Precocious puberty	37
Lipodystrophy	17	Pregnancy in adolescence/prevention and control	28*suppl
Liquid chromatography-mass spectrometry	86	Prehospital care	189
Long acting reversible contraception	28*suppl	Prevalence	55, 256
Macular retinal thickness	63	Prevention	315
Macular retinal volume	63	Progeria	17
Male adolescent	168	Progeria syndrome	315
Menstruation	41*suppl	<i>PROPI</i> gene	261
Metabolic syndrome	55, 63, 180	Puberal stage	168
Metformin	315	Puberty	37, 79, 295
Metreleptin	17	Questionnaire	95
MIRAGE syndrome	206	Rat	79
Missense mutation	212	Receptor Roundabout-1 gene	212
Mobile	125	Reliability	241
Motivational interviewing	225	Risk behaviors	233
Multiple pituitary hormone deficiency	295, 319	School-age children	256
Muscle mass	168	Second-tier	288
Mutation	104	Short stature	125, 130
Müllerian aplasia	50*suppl	Six month L-thyroxine dose	275
Myocarditis	160, 202	Soluble CD40 ligand (sCD40L)	197
National Prophylaxis Program	248	Soluble receptor for advanced glycation end-products	160
Neonatal screening	288	<i>SOX9</i>	308
Nesfatin-1	29	<i>SRY</i> -negative	308
Neurofibromatosis Noonan syndrome	113	Steroid profiling	288
Neurofibromatosis type-1	202	Subclinical hypothyroidism	143
Newborn	104	Thiol/disulfide homeostasis	45
<i>NF1</i> gene	113	Thyroid function test	143
Obesity	29, 45, 180	Thyroid hormone	197
Optical coherence tomography	63	Thyroid volume	197
Oral contraceptive pills	1*suppl	Transient	275
Orthorexic eating behavior	233	Treatment	18*suppl, 151
Osteochondromyxoma	117	Turkey	86, 256, 269, 329
Pediatric obesity	63	Turner syndrome	95
Pediatric or childhood chronic liver diseases	143	Type 1 diabetes	55, 175, 233, 281
Pediatric transport	189	Urinary iodine concentration	329
Pelvic pain	7*suppl	Urine	86
Permanent	275	Vaginal opening	79
Phenotype	1	Vitamin D	248
Pheochromocytoma	202	Zonulin	303